[1] |
Czepiel J,Drózdz M,Pituch H,et al.Clostridium difficile infection:review[J].Eur J Clin Microbiol Infect Dis,2019,38(7),1211-1221.
|
[2] |
Peng Z,Ling L,stratton CW,et al.Advances in the diagnosis and treatment of Clostridium difficile infections[J].Emerg Microbes infect,2018,7(1):15.
|
[3] |
Taneja N,Zaman K.Clostridium difficile associated diarrhea:diagnostic Challenges[J].Assoc Physicians India,2018,66(6):70-73.
|
[4] |
徐英春,张曼.中国成人艰难梭菌感染诊断和治疗专家共识[J].协和医学杂志,2017,8(2):131-138.
|
[5] |
强占荣,易彩霞,刘颖,等.慢性HBV感染者外周血淋巴细胞亚群及血清IgG 和补体检测的临床意义[J].内科,2016,11(1):1-3.
|
[6] |
Ostroumov D,Fekete-Drimusz N,Saborowski M,et al.CD4 and CD8 T lymphocyte interplay in controlling tumor growth[J].Cell Mol Life Sci,2018,75(4):689-713.
|
[7] |
Yang Y,Qin Z,Du D,et al.Safety and short-term efficacy of irreversible electroporation and allogenic natural killer cell immunotherapy combination in the treatment of patients with unresectable primary liver cancer[J].Cardio Intervent Radiol,2019,42(1):48-59.
|
[8] |
Dial S,Delaney JA,Barkun AN,et al.Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease[J].JAMA,2005,294(23):2989-2995.
|
[9] |
陈冬梅,陈求刚,陈菊香.艰难梭菌性肠炎21例[J].广东医学,2000,21(6):519.
|
[10] |
Lo Vecchio A,Zacur GM.Clostridium difficile infection:an update on epidemiology,risk factors,and therapeutic options[J].Curr Opin Gastroenterol,2012,28(1):1-9.
|
[11] |
Zilberberg MD,Reske K,Olsen M,et al.Risk factors for recurrent Clostridium difficile infection(CDI)hospitalization among hospitalized patients with an initial CDI episode:a retrospective cohort study[J].BMC Infect Dis,2014,14(1):1-8.
|
[12] |
Rineh A,Kelso MJ,Vatan sever F,et al.Clostridium difficile infection:Molecular pathogenesis and novel therapeutics[J].Expert Rev Anti Infect Ther,2014,12(1):131-150.
|
[13] |
Bobo LD,El Feghaly RE,Chen YS,et al.MAPK-activated protein kinase 2 contributes to Clostridium difficile-associated inflammation[J].Infect Immu,2013,81(3):713-722.
|
[14] |
Zhu Z,Schnell L,Müller B,et al.The antibiotic bacitracin protects human intestinal epithelial cells and stem cellderived intestinal organoids from Clostridium difficile toxin TcdB[J].Stem Cells Int,2019,11(6):1-8.
|
[15] |
Madan R,Petri WA Jr.Immun e responses to Clostridium difficile infection[J].Trends Mol Med,2012,18(11):658-666.
|
[16] |
陈轶,陈益耀,韩向阳,等.乙型肝炎病毒感染患者外周血T细胞亚群的表达特征与相关性研究[J].中华医院感染学杂志,2016,26(5):979-981.
|
[17] |
聚乙二醇干扰素α-2b 对慢性乙型肝炎患者的免疫调节及抗病毒效果分析[J].解放军医药杂志,2017,29(8):86-89.
|
[18] |
Shah PJ,Vakil N,Kabakov A.Role of intravenous immune globulin in streptococcal toxic shock syndrome and Clostridium difficile infection[J].Am J Health Syst Pharm,2015,72(12):1013-1019.
|
[19] |
Rees WD,Steiner TS.Adaptive immune response to Clostridium difficile infection:A perspective for prevention and therapy[J].Eur J Immunol,2018,48(3):398-406.
|